Skip to main content

Richard G. Gervase, Jr.

Member

[email protected]

+1.212.692.6755

Follow:
Share:

Richard is a member of the firm’s Corporate and Securities and Intellectual Property sections and is the Chair of the firm’s Royalty & Revenue Interest Financing Transactions Group. He represents leading private equity firms, lenders, and other investors and public and private companies in structured financing transactions (including royalty sales and synthetic royalty transactions), mergers and acquisitions, joint ventures, and other strategic transactions in the life sciences and technology space, as well as general corporate representation. 

Royalty Financing: Richard’s royalty finance practice includes purchases and sales of royalty interests, synthetic royalty financings, senior secured loans and credit facilities, clinical trial financings, revenue interest financings, accounts receivable financings, purchases and sales of earn-out payments, contingent value rights and priority review vouchers, and other non-dilutive financings.Richard and his team take an asset-based approach--analyzing each opportunity from an intellectual property, regulatory, bankruptcy/collateral, antitrust, contract, and pricing and reimbursement perspective to structure bespoke flexible non-dilutive financing solutions that are carefully tailored to a particular opportunity. He also represents secured lenders and other investors in bankruptcy proceedings, corporate restructurings, workouts, Section 363 sales, DIP financings and stalking horse bids involving distressed pharmaceutical and biotechnology product assets. 

Strategic Technology Transactions: Richard’s strategic technology transactions practice includes mergers and acquisitions, joint ventures, strategic alliances, pharmaceutical licenses and collaborations, technology licenses, supply and distribution agreements, co-promotion and marketing agreements, software license agreements, data license agreements, and investments and acquisitions involving life sciences and technology assets.  He also regularly advises private equity firms, hedge funds, venture funds and public and private companies in due diligence investigations in the life sciences and technology spaces.  Richard’s clients include leading investors and companies in the fields of pharmaceuticals, biotechnology, artificial intelligence & machine learning, medical technology, diagnostics, healthcare, software, semiconductors, telecommunications (including 5G and LTE), financial technology, cybersecurity, and cleantech. 

Litigation and Disputes: Richard has represented Fortune 100 companies in patent infringement litigation, trade secret litigation, trademark litigation, and copyright disputes nationwide, including both state and federal court litigation and related proceedings before the U.S. Patent and Trademark Office (USPTO), including inter-partes reviews (IPRs), post-grant reviews (PGRs), covered business method (CBM) reviews.  He also advises clients in contractual disputes involving royalty financing agreements, asset purchase agreements, license and collaboration agreements, software license agreements, research grant funding agreements, and open source software licenses. 

IP Strategy, Licensing and Enforcement: A registered patent attorney, Richard works with public and private companies in patent prosecution strategy and management, with a focus on creating strong patent portfolios for licensing and enforcement.  He advises clients on freedom-to-operate analyses, infringement and validity analyses, intellectual property opinions and intellectual property due diligence.  He also advises clients in matters involving copyright fair use and IP-related antitrust matters, including monopolization claims, reverse payment arrangements, FRAND licensing and standards-essential patents, patent misuse, tying arrangements, exclusive dealing arrangements, grant-backs and cross-licenses, patent pooling arrangements, and price controls.

Richard is a member of the firm’s Opinion Committee and Contingency Fee Committee.  He is also a member of the firm’s Life Sciences Practice Group. 

He completed executive mediation training at Harvard Law School’s Program on Negotiation. He was Senior Articles Editor for the Rutgers Law Journal.

Prior to joining Mintz in 2000, Richard was a senior patent litigation attorney at Fish & Neave in New York City.  He started his legal career in the late 1980’s as a mergers and acquisitions and securities lawyer at Brown & Wood focused on the biotechnology and life sciences sectors.

Richard rowed competitively in college on the Rutgers Lightweight Crew Team.  An avid skier, Richard is on the Board of Governors of the Amateur Ski Club of New York and has served on the Finance Committee of Mad River Glen in Fayston, VT.

Experience

Royalty and Revenue Interest Financing Transactions

  • Represented Sixth Street Partners in a non-dilutive senior secured credit facility of up to $475 Million for Apellis Pharmaceuticals, which received $375 million in funding at close, with ability to access an additional $100 million under the facility at the Company’s option prior to September 2025, subject to the satisfaction of certain conditions.
  • Represented Daré Bioscience, Inc. in a $22 million non-dilutive strategic royalty and revenue interest financing with XOMA (US) LLC involving: (i) a traditional royalty purchase of certain net royalties and net milestones payable with respect to net sales  of XACIATO (clindamycin phosphate) (net of (i) payments owed to an upstream licensor and (ii) payments owed to an existing royalty investor), and (ii) a synthetic royalty purchase involving royalties payable on net sale of Ovaprene and Sildenfil Cream.
  • Represented a private equity-backed biopharmaceutical company in the monetization of its entitlement to receive certain contingent earn out payments in connection with the sale of four commercial pharmaceutical products to a publicly traded biopharmaceutical company.
  • Represented two leading private equity investors in the bankruptcy of one of their portfolio companies, and the acquisition of certain pharmaceutical royalty and product assets out of bankruptcy.
  • Represented TheracosBio in a royalty financing agreement with HealthCare Royalty with respect to certain future royalties and milestone payments from the commercialization of a veterinary product developed by TheracosBio and commercialized by Elanco Animal Health.
  • Represented Sagard Healthcare Partners in its $400 million acquisition of a portion of uniQure N.V.’s royalty interest in HEMGENIX (etranacogene dezaparvovec-drbl).
  • Represented a leading private equity investor in connection with the bankruptcy of one of its portfolio investments, including as a potential bidder in a 363 acquisition of certain pharmaceutical product assets via credit bid.
  • Represented Sagard Healthcare Partners in a $32.5 million revenue interest financing agreement with Marinus Pharmaceuticals related to ZTALMY® (ganaxolone), a novel therapy for the treatment of seizure disorders.
  • Represented Sagard Healthcare Partners in a $131.8 million sale of rights to a 5% portion of royalty interests in TIBSOVO® from Agios Pharmaceuticals, Inc. 
  • Represented Sagard Healthcare Partners and Oaktree Capital Management in acquiring royalty and milestone interests in Klisyri® (tirbanibulin) from Athenex, Inc. for $85 million.  
  • Represented an inventor of Xenpozyme (olipudase alpha-rpcp) in the sale of his Xenpozyme royalty entitlement under a collaboration agreement with Sanofi Genzyme. 
  • Represented Cystic Fibrosis Foundation in the sale of its residual royalty interest in Vertex Pharmaceutical’s cystic fibrosis (CF) treatments to Royalty Pharma plc. The proceeds of the sale ($575 million upfront with potential milestone payments of $75 million) will further support the CF Foundation’s work to fund research and drug development and advance high-quality specialized CF care.
  • Represented Sixth Street Partners in a $500 million synthetic royalty financing for Biohaven Pharmaceuticals. The proceeds of the loan facility were used for the development, promotion and commercial launch of Nurtec ODT (rimegepant), a drug used for the treatment of acute migraine.
  • Represented Albireo Pharma, Inc. in the sale of its priority review voucher for $105 million.  Albireo received the voucher with the approval of Bylvay for the treatment of pruritus in all types of progressive familial intrahepatic cholestasis (PFIC).
  • Represented Massachusetts General Hospital and Partners HealthCare in the sale of a portion of their royalty interest in Entyvio (vedolizumab) to Royalty Pharma for $94MM.  Entyvio is a monoclonal antibody that is used in the treatment of ulcerative colitis and Crohn’s disease.  Entyvio is based on a cell line that was developed in the laboratory of Dr. Robert Colvin at MGH.  Entyvio generated approximately $2.5 billion in worldwide sales in FY 2019.
  • Represented TPG Sixth Street Partners in a $300 million synthetic royalty senior secured debt financing by Therapeutics MD, an innovative pharmaceutical company committed to advancing the health of women and championing awareness of their healthcare issues. The financing was based on sales of IMVEXXY, BIJUVA and ANNOVERA.
  • Represented TPG Sixth Street Partners in a $175 million synthetic royalty clinical trial financing for Clovis Oncology. The proceeds were used to fund the ATHENA first-line maintenance clinical trial for Rubraca’s use in treating ovarian cancer.
  • Represented ImmunoGen, Inc. in a royalty financing transaction raising $65 million involving the sale of ImmunoGen’s residual worldwide royalties based on sales of KADCYLA® to an investment fund managed by the Ontario Municipal Employees Retirement System (OMERS). 
  • Represented TPG Sixth Street Partners in a $225 million investment in senior secured debt, convertible notes and warrants for Caris Life Sciences, a molecular profiling company focused on precision medicine.
  • Represented an inventor in the sale by Boston Children’s Hospital of both the Hospital’s and the inventor’s share of their respective royalty interests in Vonvendi to an affiliate of Barings Alternative Investments for over $60 million.  
  • Represented Albireo Pharma, Inc. and its Swedish subsidiary Elobix AB in the sale to HealthCare Royalty Partners for $45 million (up to $60 million if a certain sales milestone is met) of Elobix’s right to receive royalties and certain milestones for sales of elobixibat in Japan, up to a certain threshold. 
  • Represented CLS Pharmaceuticals in the sale of its rights to future royalties with respect to SHP-640, a combination broad spectrum antiseptic and corticosteroid Phase III asset being developed by Shire for the treatment of infectious conjunctivitis to a prominent venture fund for an undisclosed amount. 
  • Represented TPG Sixth Street Partners in a $150 million synthetic royalty debt financing by Ironwood Pharmaceuticals relating to sales of Linzess (linaclotide).
  • Represented TPG Special Situations Partners in a $250 million senior secured debt financing by Nektar Therapeutics backed by various royalty streams held by Nektar. 
  • Represented ARIAD, Inc. in a synthetic royalty financing transaction raising $200 million in non-dilutive financing backed by a portion of ARIAD’s revenue interest on sales of Iclusig® to an investment fund managed by PDL BioPharma, Inc. 
  • Represented ImmunoGen, Inc. in a royalty financing transaction raising $200 million in non-dilutive financing involving the sale of a portion of ImmunoGen’s royalties based on sales of KADCYLA® to TPG Special Situation Partners. 
  • Represented Intarcia Therapeutics in a novel $225 million synthetic royalty financing with equity conversion option at a $5.5 billion valuation based on future global net sales of its diabetes pump product candidate ITCA 650.  
  • Represented Vertex Pharmaceuticals in its $155 million debt financing secured by future milestones associated with the filing, approval, and launch of its hepatitis C (HCV) protease inhibitor drug candidate telaprevir in Europe to an affiliate of Olmsted Park.  
  • Represented Vertex Pharmaceuticals in the sale of its rights to an aggregate of $95 million in potential future milestones tied only to the launch of telaprevir in the European Union to an affiliate of Olmsted Park.
  • Represented Drug Royalty Corporation in the purchase of 25% of Enzon Pharmaceuticals, Inc.’s worldwide royalty interest in PEG-INTRON (peginterferon alpha-2b) for $92 million (plus an additional $15 million if certain royalty recognition levels be met).
  • Represented Drug Royalty Corporation in the acquisition of a portion of ISIS Pharmaceuticals, Inc.’s rights to receive royalties generated by Macugen (pegaptanib sodium injection) for $24 million. 
  • Represented Drug Royalty Corporation in multiple transactions involving the acquisition of royalties generated by blockbuster drug Remicade.

License and Collaboration Agreements

  • Represented BioNTech SE in its $1.6 billion global strategic partnership with Duality Biologics (Suzhou) Co. Ltd. to accelerate development of differentiated antibody-drug conjugate therapeutics for solid tumors.
  • Represented Grünenthal GmbH in the license of exclusive commercial rights for the dermal pain patch Qutenza (8% capsaicin) in the US, Latin America, Asia and Australia from Acorda Therapeutics, Inc. 
  • Represented ARIAD Pharmaceuticals, Inc. in a license and collaboration agreement with Incyte Corporation whereby ARIAD granted to Incyte an exclusive license to develop and commercialize ARIAD’s kinase inhibitor Iclusig (ponatinib) in Europe.
  • Represented LAM Therapeutics, Inc. in an exclusive license and collaboration agreement with an undisclosed party for the worldwide development of certain Hsp90 inhibitors.
  • Represented Grünenthal GmbH in the acquisition of exclusive commercial rights for the dermal pain patch Qutenza (8% capsaicin) in Europe, the Middle East, and Africa from Astellas Pharma Europe Ltd.
  • Represented a venture-backed drug development company in an exclusive license and collaboration agreement with Synta Pharmaceuticals Corp. for the worldwide development and commercialization of certain IL-12 and IL-23 inhibitors.
  • Represented a venture-backed drug development company in a Master Clinical Supply and Development Agreement with F. Hoffmann-La Roche Ltd. for the joint development of a LAM proprietary compound.
  • Represented Altus Pharmaceuticals Inc. in a development, commercialization and marketing agreement with Dr. Falk Pharma GmbH for the development of ALTU-135 (TheraCLEC) in Europe, the Soviet Union, Israel and Egypt.
  • Represented Altus Pharmaceuticals Inc. in an exclusive license and collaboration agreement with Cyctic Fibrosis Foundation Therapeutics, Inc. for the development of ALTU-135 (TheraCLEC) and certain other derivatives in North America.
  • Represented OSI Pharmaceuticals, Inc. in a global Co-Development and Commercialization Agreement with Genentech Inc. and Roche for the development and commercialization of OSI’s lead cancer drug OSI-774 (Tarceva).  Under the agreement, Genentech and OSI employed an equal cost and profit sharing arrangement for commercialization in the United States, while Roche pays royalties on net sales to OSI in markets outside of the United States. The overall costs of the tripartite development program are split equally among the three parties.

M&A Transactions

  • Represented ARIAD Pharmaceuticals, Inc. in the sale of its European operations to Incyte Corporation and a corresponding license agreement for Incyte to exclusively license Iclusig® in Europe and other select countries.
  • Represented Dainippon Sumitomo Pharma Co. Ltd. in its acquisition of Sepracor Inc. for $2.55 billion.
  • Represented Humedica Inc. in its acquisition by UnitedHealth Group Inc.
  • Represented Qiagen NV in its acquisition of Digene Corp. for $1.6 billion.
  • Represented Vertex Pharmaceuticals Incorporated in its acquisition of ViroChem Pharma, Inc. for $400 million.
  • Represented Myriad Genetics, Inc. in its acquisition of Rules-Based Medicine, Inc. for $80 million. 
  • Represented CuraGen Corporation in the sale of its next-generation sequencing subsidiary 454 Life Sciences Corporation to Roche for $155 million.
  • Represented AT&T Corp. as special patent counsel in connection with its trivestiture/spin-off of NCR Corporation and Lucent Technologies.

Litigation

  • Represented a public, not-for-profit foundation in a dispute involving the failure by a grant recipient to pay royalties and other amounts due under a research grant agreement.
  • Represented UnitedHealth Group and its subsidiary Optum Inc. as lead counsel in a patent infringement suit brought by Siemens Medical Systems alleging infringement of four Siemens patents directed to the use of artificial intelligence for data mining electronic medical records, disease modeling, and use of ontologies and natural language processing for data extraction.
  • Represented a leading royalty investor in a breach of contract dispute with a royalty seller.
  • Represented a leading medical center in a breach of contract dispute with a global pharmaceutical company over milestones and royalties due and owing under a research collaboration agreement. 
  • Represented a global sports equipment manufacturer in a patent, copyright, trademark and trade dress dispute with a copycat competitor involving treadmills and stationary bicycles.
  • The Brita Products Company v. Seventh Generation, Inc. (N.D. Cal.) – Represented Seventh Generation in a declaratory judgment action brought by plaintiff Brita seeking to invalidate two Seventh Generation patents directed to refillable water bottles containing water filtration devices.
  • Krauser v. BioHorizons, Inc. (S.D. Fla.) – Defended BioHorizons in a dispute over ownership and inventorship of technology and patents directed to dental implants. Disposed of on summary judgment and BioHorizons was awarded its attorney’s fees.
  • Round Rock Research LLC v. HTC Corp. (D. Del.) – Defended HTC in a patent infringement suit alleging infringement of five patents directed to 3G and 4G wireless chipsets and smartphone technologies.
  • Rates Technology Inc. v. Nortel Networks Corp. (E.D.N.Y.) – Defended Nortel in a patent infringement lawsuit involving three patents directed to computer telephony switching infrastructure. Disposed of on a motion to dismiss affirmed by the Federal Circuit.
  • Cardiofocus, Inc. v. Lumenis, Inc. (D. Mass.) – Defended Lumenis in a patent infringement case involving three patents directed to medical lasers.
  • Altus Biologics Inc. v. Altus Medical, Inc. (S.D.N.Y.) – Represented Altus Biologics in a trademark infringement suit involving the company’s registered trademark Altus.
  • DePuy Spine Inc. et al. v. Alphatec Spine, Inc. (D. Mass.) – Defended Alphatec in a patent infringement lawsuit involving a DePuy patent directed to polyaxial pedicle screws.
  • Louis Vuitton Malletier v. Dooney & Bourke, Inc. (S.D.N.Y) – Represented Louis Vuitton in a trademark infringement lawsuit involving Vuitton’s colorful and hot-selling Murakami handbags.
  • Richter Gedeon Vegyeszeti Gyar RT v. Gyma Laboratories, Andrx Corp., et al. (E.D.N.Y.) – Represented Richter Gedeon in a patent infringement lawsuit involving infringement of five Richter Gedeon patents directed to crystallised polymorph versions of famotidine.
  • Motorola, Inc. v. Rockwell International Corporation (D. Del.) – Represented plaintiff Motorola in patent infringement suit involving 11 patents relating to trellis coded modulation and other telecommunication technologies used in computer modem chipsets. Case involved complex antitrust and misuse defenses stemming from the standard-setting process.
  • Duplitronics Inc. v. Time Warner Inc. (N.D. Ill.) – Defended Time Warner in a patent lawsuit alleging infringement of three Duplitronics patents directed to compact discs and memory storage technologies.
  • Altera v. Xilinx/Xilinx v. Altera (N.D. Cal.) – Represented Altera in two patent infringement lawsuits (one as a plaintiff and the other as a defendant) involving the parties’ respective patents directed to computer chip architecture and programmable logic devices.
  • Lucent Technologies Inc. v. Periphonics Corp. (D. Del.) – Represented plaintiff Lucent in patent infringement suit involving six patents relating to computer telephony, voice recognition, interactive voice response, and voice messaging system technologies.
  • Lucent Technologies Inc. v. Microchip Technology Inc. (D. Del.) – Represented plaintiff Lucent in patent infringement suit involving five patents relating to photolithography and other technologies used in the fabrication and architecture of high-performance computer chips.
  • Motorola, Inc. v. PC Tel, Inc. (D. Del.) – Represented plaintiff Motorola in patent infringement suit involving 10 patents relating to various modem technologies.
  • NCR Corporation v. Netscape Communications Inc. (D. Del.) – Represented plaintiff NCR in patent infringement suit involving 10 NCR patents directed to various Internet-related technologies including certain client-server architecture, database management, and encryption technologies.
  • Cochlear Corp. v. Advanced Bionics (N.D. Cal.) – Defended Advanced Bionics (a subsidiary of Boston Scientific) in a patent infringement lawsuit involving two patents directed to cochlear implant technology.
  • Gillette Canada v. Thornton Int’l. (D. Conn.) – Represented plaintiff Gillette in a patent infringement lawsuit alleging infringement of two Gillette patents directed to dental floss.

Artificial Intelligence

  • Represented a global pharmaceutical company in a patent landscape analysis focused on the use of artificial intelligence and real world data in drug discovery. 
  • Represented a venture-backed life sciences company as bidders in a Section 363 asset sale out of bankruptcy of a portfolio of early patents directed to the use of AI for drug discovery and development and performed validity studies and infringement analyses as part of a freedom to operate review. 
  • Represented numerous life sciences companies in the negotiation of licenses for the use of data and materials (including medical data, tissue cohorts and associated (anonymized) longitudinal clinical data) with commercial providers, leading medical centers, and academic institutions for use in training predictive AI models. 
  • Represented a Fortune 10 global healthcare company as lead counsel in a patent infringement suit involving patents directed to the use of artificial intelligence for data mining electronic medical records, disease modeling, and use of ontologies and natural language processing for data extraction.
  • Represented a life sciences diagnostic company in the creation of a substantial patent portfolio directed to systems and methods utilizing artificial intelligence, machine learning and machine vision to predict disease progression, which resulted in the development of a lab developed test for predicting the recurrence of cancer. 
  • Advised various life sciences and software companies regarding the use of copyrighted content in the training of generative AI models and the use of open source software in commercial product offerings. 
Read less

viewpoints

Read about a Third Circuit ruling, which held that a creditor’s right to future royalty payments in a non-executory contract — an agreement in which one party has performed all material obligations and the other has not — could be discharged in the bankruptcy of a counterparty-debtor. The decision highlights the importance of properly structuring M&A, earn-out, and royalty-based transactions.

Read more
Amid the continuing threat to U.S. intellectual property rights posed by foreign actors, the International Trade Commission (ITC) is poised to become the latest federal agency to bolster protections for U.S. IP owners. The ITC’s broad power to exclude the importation into the U.S. of products that infringe American intellectual property now has the potential to be made even more robust through a new bill introduced by Senators John Cornyn (R-Tex.), Christopher Coons (D-Del.), and Todd Young (R-Ind.) on June 15, 2021, that would provide expedited relief for trade secret theft victims.
Read more
In a reversal that came as no surprise to many observers, on Tuesday, August 11, 2020, a unanimous panel of the U.S. Court of Appeals for the Ninth Circuit reversed the decision by the U.S. District Court for the Northern District of California in FTC v. Qualcomm and vacated the district court’s worldwide, permanent injunction prohibiting several of Qualcomm Incorporated’s (“Qualcomm”) licensing practices with respect to standard-essential patents (“SEPs”) covering cellular technology.
Read more
In a recent decision in In Re Humira (Adalimumab) Antitrust Litigation), No. 19-cv-1873, Judge Shah of the Northern District of Illinois dismissed a consolidated class action complaint filed by U.S. purchasers of AbbVie Inc.’s blockbuster biologic drug Humira alleging that AbbVie had prevented manufacturers of competing biosimilar drugs (“biosimilars”) from entering the U.S. market in violation of federal and state antitrust laws.
Read more
Viewpoint Thumbnail
Just when observers thought Qualcomm could celebrate its successful litigation with Apple another decision has come down which could have major implications for Qualcomm’s business going forward.
Read more
The Supreme Court has made it easier for patent owners to prove willful infringement and entitlement to enhanced damages.
Read more
On Wednesday, President Obama signed into law the groundbreaking Defend Trade Secrets Act (DTSA)1, which for the first time creates a federal civil remedy for trade secret misappropriation and provides uniformity (and hopefully predictability) to what has, until this point, been a patchwork body of law applied disparately among the states.
Read more
On December 17, 2015, the Federal Circuit issued a precedential decision affirming a determination by the Patent Trial and Appeal Board (“PTAB”) that patent claims related to methods of treating elevated homocysteine levels were invalid as obvious.
Read more
Last month, the Ninth Circuit Court of Appeals issued a pivotal decision in Microsoft v. Motorola regarding the licensing of standard essential patents (SEPs) on reasonable and non-discriminatory (RAND) terms.
Read more
Late last month, the Ninth Circuit Court of Appeals issued its much-anticipated decision in Microsoft v. Motorola, a breach of contract action brought by Microsoft alleging that Motorola violated its commitment to license its standard essential patents (SEPs) on reasonable and non-discriminatory (RAND) terms.
Read more
Read less

News & Press

Press Release Thumbnail

A Mintz team led by Richard Gervase, Member and Chair of the firm’s Royalty & Revenue Interest Financing Transactions Group, advised global investment firm Sixth Street in a non-dilutive, senior secured credit facility of up to $475 million for Apellis Pharmaceuticals. Apellis received $375 million in funding at close, with ability to access an additional $100 million under the facility at the Company’s option prior to September 2025, subject to the satisfaction of certain conditions.

Press Release Thumbnail

NEW YORK – Mintz is pleased to announce that 18 attorneys have been named New York Metro Super Lawyers and 11 attorneys have been named New York Metro Rising Stars by Super Lawyers for 2023.

Press Release Thumbnail

Mintz is pleased to announce that 120 firm attorneys have been recognized as leaders by Best Lawyers® in the 2024 edition of The Best Lawyers in America©.

Press Release Thumbnail

17 Mintz attorneys have been named New York Metro Super Lawyers and nine Mintz attorneys have been named New York Metro Rising Stars by Super Lawyers for 2022.

Press Release Thumbnail

Best Lawyers® recognized 108 firm attorneys in the 2023 edition of The Best Lawyers in America©. Notably, two Mintz attorneys – Poonam Patidar and Scott M. Stanton – received 2023 “Lawyer of the Year” awards, and 28 firm attorneys were included in the inaugural edition of Best Lawyers: Ones to Watch.

News Thumbnail
Mintz Member and head of the firm’s Royalty Monetization Practice Richard Gervase authored an article published by Intellectual Asset Management (IAM) on royalty monetization transactions and how they can generate cash for life sciences innovators.
Read less

Events & Speaking

Panelist
Oct
31
2023

Working Group on Legal Opinions Foundation

Fall 2023 Legal Opinions Seminar

New York, NY

Seminar Reference Image
Panelist
Sep
7
2023

ABA Business Law Section Fall Meeting

Fall 2023 Legal Opinions Seminar

Chicago, IL

Seminar Reference Image
Panelist
Oct
12
2018

Reconfiguring the Landscape for the Alzheimer's Challenge Workshop

MIT Sloan School of Management, Laboratory of Financial Engineering

Wequassett Resort, Harwich, MA

Panelist
Oct
27
2015

Sinai Innovations Conference 2015

Icahn School of Medicine at Mount Sinai

New York, New York

Read less

Recognition & Awards

  • Best Lawyers in America (2023 - 2024)

  • New York Super Lawyers (2022 - 2023)

Read less

Involvement

  • MIT Sloan School of Management, Laboratory of Financial Engineering, speaker and participant
  • American Bar Association, Business Law Section, IP Opinions Task Force, member of Drafting Committee for ABA Report “Third-Party Legal Opinions and Negative Assurance Letters to Underwriters Covering Intellectual Property Matters
  • American Bar Association, Intellectual Property Law Section, member Patent Litigation Committee
  • Working Group on Legal Opinions Foundation (WGLE), member and speaker
  • Lecturer and Advisor to the Harvard-MIT Health Sciences and Technology (HST) Program at the MIT Institute for Medical Engineering and Science
  • Lecturer and Advisor to the Runway Postdoctoral Program at the Joan and Irwin Jacobs Technion-Cornell Innovation Institute (TCII)
  • Biotech Industry Organization (BIO), member and speaker
  • Intellectual Property Owners Association (IPO), member
  • American Intellectual Property Law Association (AIPLA), Patent Litigation Committee
  • New York Intellectual Property Law Association (NYIPLA), Patent Litigation Committee
  • Federal Circuit Bar Association, Amicus Committee
  • Licensing Executive Society (LES), member and speaker
  • Finance Committee, Mad River Glen (Fayston, VT)
  • Board of Governors, Amateur Ski Club of New York (Fayston, VT)
Read less